Needham & Company Maintains Buy on Hyperion Therapeutics (HPTX) Post Q4
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Hyperion Thptcs (HPTX) Posts Q4 Loss of 50c/Share
February 25, 2013 6:25 AM ESTHyperion Thptcs (NASDAQ: HPTX) reported Q4 EPS of ($0.50), $0.12 worse than the analyst estimate of ($0.38).
For earnings history and earnings-related data on Hyperion Thptcs (HPTX) click here.... More
